Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Passes Above Fifty Day Moving Average – Should You Sell?

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) passed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $0.22 and traded as high as $0.35. Eagle Pharmaceuticals shares last traded at $0.35, with a volume of 102 shares.

Eagle Pharmaceuticals Trading Up 2.6%

The firm has a market capitalization of $4.55 million, a P/E ratio of 0.30 and a beta of 0.83. The business’s 50 day simple moving average is $0.22 and its two-hundred day simple moving average is $0.66.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Woodcliff Lake, New Jersey, that focuses on the development, manufacturing and commercialization of hospital-administered therapies in the areas of critical care, oncology and rare diseases. Founded in 2007, Eagle has built expertise in complex injectable formulations and orphan drug designation, aiming to address unmet medical needs through both novel products and reformulated generics.

The company’s marketed portfolio in the United States includes Bendeka®, an intravenous formulation of bendamustine for certain types of leukemia and lymphoma; Beleodaq®, approved for relapsed or refractory peripheral T-cell lymphoma; and Empaveli®, a complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria.